FRANKFURT, April 5 (Reuters) - Morphosys still believes that its MOR202 compound has a good chance of becoming a success after U.S. drugmaker Celgene scrapped cooperation on the drug candidate, the German company's chief executive told a newspaper.

from Reuters: Company News http://ift.tt/1EYdJy1
via IFTTT
from Reuters: Company News http://ift.tt/1EYdJy1
via IFTTT
No hay comentarios:
Publicar un comentario